Mid-Point Analysis of Pivotal Phase 3 SIERRA Trial Including Material Presented at 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (TCT)
225Ac-CD38 Antibody Targeting is Effective and Well Tolerated in Experimental Models of Lymphoma and Multiple Myeloma
Targeted Lymphodepletion with Radiolabeled CD45 antibody as a Preparative Regimen Prior to Adoptive Cell Therapy
Rapid reduction of peripheral blasts in older patients with refractory acute myeloid leukemia (AML) using reinduction with single agent anti-CD45 targeted iodine (131I) apamistamab [Iomab-B] radioimmunotherapy in the phase III SIERRA trial.
![Rapid reduction of peripheral blasts in older patients with refractory acute myeloid leukemia (AML) using reinduction with single agent anti-CD45 targeted iodine (131I) apamistamab [Iomab-B] radioimmunotherapy in the phase III SIERRA trial.](https://d1io3yog0oux5.cloudfront.net/_7a2918fdd62a2e2a672c4dae91f27b56/actiniumpharma/db/206/925/pdf_thumbnail.jpg "Rapid reduction of peripheral blasts in older patients with refractory acute myeloid leukemia (AML) using reinduction with single agent anti-CD45 targeted iodine (131I) apamistamab [Iomab-B] radioimmunotherapy in the phase III SIERRA trial.")
